Thailand's New Registration Documentation Requirements for Hazardous Substances

Thailand's FDA issued a notice titled "Re: Determination of the List of Data, Documents, and Evidence for Hazardous Substance Registration, B.E. 2568," signed September 26, 2025 and published in the Royal Gazette on October 20, 2025, that resets the list of data, documents, and evidence applicants must submit when registering a hazardous substance in Thailand. Per the notice's own transitional clause, it took effect 30 days after Royal Gazette publication, November 19, 2025, and it now governs what a complete registration dossier looks like for anyone filing after that date. For companies with a registration already in preparation, or a renewal coming up, the practical question is not whether the notice exists but whether the file being assembled right now still matches what Thai FDA is actually asking for.

What the notice does

The notice sits inside Thailand's Hazardous Substances Act B.E. 2535 (1992) framework as a subordinate administrative instrument, the kind of document a competent authority issues periodically to specify, in operational detail, exactly what a registration application file has to contain. The Act itself sets the legal structure for registration, refusal grounds, and enforcement; notices like this one translate that structure into the concrete checklist a reviewing officer works from when a file lands on their desk. Thai FDA has issued and revised this kind of document list before, and doing so again in late 2025 is consistent with an authority periodically tightening or reorganizing its documentation expectations rather than announcing a change to the underlying registration process itself.

That distinction matters for how a company should read this update. A notice resetting the required data, documents, and evidence list is not the same as a change to registration types, classification tiers, or the legal grounds on which Thai FDA can refuse a filing. It is a refresh of the submission checklist, the specific items, formats, and supporting evidence a Type 2 or Type 3 hazardous substance applicant has to hand over for the Bureau to consider the application complete enough to review on its merits.

Why a documentation refresh carries real practical weight

It is tempting to treat a notice about document lists as a housekeeping matter that a compliance team can skim and file away. In practice, this is exactly the kind of update that causes the most avoidable friction for companies actively registering products. A dossier assembled against an outdated document checklist, one built from a template used successfully six months earlier, an old law firm memo, or a distributor's boilerplate submission package, can look complete to the company preparing it while still being incomplete under the current requirement. The reviewing officer at Thai FDA is not working from what was required a year ago. They are working from what the November 2025 notice specifies today.

This is precisely the gap that produces the documentation-level delays we cover in why hazardous substance registrations get rejected or delayed in Thailand: not a legal refusal under Section 38 of the Act, but a request for additional documents that resets the review clock because something in the submitted file did not match current expectations. A documentation list update is a direct, traceable cause of exactly that kind of delay when a company files without checking whether its dossier still lines up with the current notice.

Who this affects

Any company registering a new hazardous substance with Thai FDA after November 19, 2025 is filing under this notice, whether or not anyone on the project team is aware it exists. That includes household chemical products, disinfectants, and cleaning agents, along with industrial-use hazardous substances falling under the FDA's jurisdiction, generally the products classified under Lists 4.1 and 4.2 of the hazardous substance schedule that Thai FDA, rather than another ministry, has authority to register. It also reaches companies renewing an existing registration or amending a previously registered formulation, since a renewal or amendment application is still measured against whatever the current documentation notice requires, not against the version in force when the original registration was filed.

Companies furthest along in their registration timeline carry the most exposure here. A dossier that was substantially built before November 2025 and is only now being finalized for submission is the highest-risk case, since the team preparing it may not have had a reason to revisit the document list after the notice took effect partway through their preparation work. This applies just as much to a foreign manufacturer working through a local distributor or a Thai-incorporated affiliate as it does to a company managing the filing directly, since the notice governs what the reviewing officer expects regardless of who physically assembles the submission.

It is also worth being specific about what a notice like this typically touches, based on how Thai FDA has structured comparable document-list updates in the past. These notices generally specify which forms are required, what supporting technical data has to accompany a given product category, how evidence such as laboratory test results or safety documentation should be formatted and presented, and what corporate or legal-status documents the applicant itself has to provide. A company should not assume the update only affects one narrow category of product or one specific document; the safer working assumption is that the entire submission checklist has been reissued and needs to be checked line by line rather than spot-checked against memory of what used to be required.

What to do before filing

The straightforward response to a documentation notice like this one is to treat dossier verification as its own discrete step, not something folded into a general final review. Before submitting a new registration, a renewal, or an amendment, confirm directly against Thai FDA's current published requirements, available through the Bureau of Hazardous Substance Control's own archive at hazard.fda.moph.go.th, that every item in the file matches what is currently specified, rather than relying on what a template, a prior successful filing, or an intermediary's standard package assumes is still current.

This is a low-cost check relative to the cost of getting it wrong. Confirming the current document list takes a fraction of the time that a rejected or incomplete filing costs once it is already in the review queue, where a documentation gap discovered by a Thai FDA officer means a formal request for additional materials, a reset review clock, and in some cases a multi-month delay to a market entry timeline that was built around the assumption of a clean first-pass filing. Building this verification step into the standard pre-submission process, rather than treating it as optional due diligence, is the single most direct way a company protects itself against a notice like this one becoming an unplanned setback.

The broader pattern worth watching

This notice is one piece of a wider trend in how Thai FDA administers the hazardous substance regime. Ministerial Regulation No. 5 (2025) digitized the application process itself, and periodic documentation notices like this one refine what goes into that digital submission once the process is underway. Companies that treat Thai FDA hazardous substance compliance as a static requirement, verified once at the start of a market entry project and never revisited, are the ones most likely to be caught out by an update like this. Companies that build in a habit of checking current requirements immediately before each filing, rather than assuming last year's checklist still holds, are the ones that keep clearing registrations on the first pass.

DeeMED verifies current Thai FDA documentation requirements directly against the Bureau's own published notices before any registration file goes in, as part of our hazardous substance registration and licensing work, so a client's dossier is built against what Thai FDA is actually asking for today, not what a template assumed a year ago.